A GATA4-regulated tumor suppressor network represses formation of malignant human astrocytomas
Open accessThe DOI matches its Crossref record; 51 of the 53 references it cites were found in a registry or an index.
Abstract
Glioblastoma Multiforme (GBM), the most common and lethal primary human brain tumor, exhibits multiple molecular aberrations. We report that loss of the transcription factor GATA4, a negative regulator of normal astrocyte proliferation, is a driver in glioma formation and fulfills the hallmarks of a tumor suppressor gene (TSG). Although GATA4 was expressed in normal brain, loss of GATA4 was observed in 94/163 GBM operative samples and was a negative survival prognostic marker. GATA4 loss occurred through promoter hypermethylation or novel somatic mutations. Loss of GATA4 in normal human astrocytes promoted high-grade astrocytoma formation, in cooperation with other relevant genetic alterations such as activated Ras or loss of TP53. Loss of GATA4 with activated Ras in normal astrocytes promoted a progenitor-like phenotype, formation of neurospheres, and the ability to differentiate into astrocytes, neurons, and oligodendrocytes. Re-expression of GATA4 in human GBM cell lines, primary cultures, and brain tumor–initiating cells suppressed tumor growth in vitro and in vivo through direct activation of the cell cycle inhibitor P21CIP1, independent of TP53. Re-expression of GATA4 also conferred sensitivity of GBM cells to temozolomide, a DNA alkylating agent currently used in GBM therapy. This sensitivity was independent of MGMT (O-6-methylguanine-DNA-methyltransferase), the DNA repair enzyme which is often implicated in temozolomide resistance. Instead, GATA4 reduced expression of APNG (alkylpurine-DNA-N-glycosylase), a DNA repair enzyme which is poorly characterized in GBM-mediated temozolomide resistance. Identification and validation of GATA4 as a TSG and its downstream targets in GBM may yield promising novel therapeutic strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



![Figure 4. Re-expression of GATA4 suppresses cell proliferation and in vivo tumor growth. (A) Transient expression of GATA4 under a constitutive active CMV promoter or empty vector control (EV) decreases proliferation in several GBM cell lines of varying genetic backgrounds. *, P < 0.01 (B) Transient expression of GATA4 leads to attenuation of cyclin D1 with increased levels of P21CIP1 and P15INK4B. (C and D) Doxycycline was added to U87 GBM cell line expressing GATA4 under a doxycycline-inducible promoter. (C) At indicated time points, GATA4, P21CIP1, and CCND1 were measured by Western blotting. (D) At the indicated times, cells in culture were counted. *, P = 0.001. (E) Survival curve of NOD-SCID mice were injected with intracranial xenografts of U87 cells with GATA4 under doxycycline (DOX)-inducible promoter. Mice were continually given doxycycline in drinking water (GATA4 on, n = 10) or no doxycycline (GATA4 off, n = 10). (F) Immunohistochemical analysis of protein markers from tumors of mice not given dox (no GATA4) versus mice given dox (GATA4). Bars: (first H&E column) 500 µm; (second [magnified] H&E column) 50 µm; (GATA4, P21-CIP1, and ki67 columns) 25 µm. (G) Quantification of protein staining from F. n = 5 mice. *, P < 0.01. Mean and SEM are shown. A and D were performed in triplicate with mean and SEM reported.](https://figures.cochat.ai/paper-figures/e27f9fa4163d45d392526cacac7e15a2/a-gata4-regulated-tumor-suppressor-network-represses-formation-of-malignant-figure-4.jpg)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“GATA4 is frequently silenced in lung, colon, prostate, ovarian, and breast cancer (38, 39).”
From The DNA damage response induces inflammation and senescence by inhibiting autophagy of GATA4. (2015) · cites this paper as [39]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,397 · cited 1×
“GBMs have been categorized into either primary or secondary subtypes (Louis et al., 2007).”
BackgroundComprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Self-citationVerhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575 · cited 2×
“Toward this goal, several approaches have been undertaken, including recent genome-wide sequencing approaches, which have pointed to a large number of novel and known genetic alterations present in GBMs (Cancer Genome Atlas Research Network, 2008; Parsons et al., 2008; Verhaak et al., 2010).”
BackgroundIdentification of human brain tumour initiating cells
Singh, S. K., Hawkins, C., Clarke, I. D., Squire, J. A., Bayani, J., Hide, T., Henkelman, R. M., Cusimano, M. D., & Dirks, P. B. (2004) · Nature · doi:10.1038/nature03128 · Cited by 7,433 · cited 1×
“These BTICs are able to selfrenew, proliferate, and give rise to different lineages (Singh et al., 2004; Stiles and Rowitch, 2008).”
BackgroundSelf-citationMGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405 · cited 1×
“We next used established and primary GBM cell lines (Sarkaria et al., 2006) to evaluate whether the GATA4mediated sensitization was dependent on TP53 status and MGMT, the DNA repair enzyme which is most often implicated in temozolomide resistance (Hegi et al., 2004, 2005).”
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857 · cited 17×
“Promoter methylation and somatic mutations silence GATA4 expression To establish the etiology of GATA4 loss in human GBMs, we first determined whether there was epigenetic silencing by hypermethylation of the GATA4 promoter, as demonstrated in lung and colon cancer (Akiyama et al., 2003; Guo et al., 2004; Hellebrekers…”
BackgroundInfluentialNonsense-mediated mRNA decay: splicing, translation and mRNP dynamics
Maquat, L. E. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1310 · Cited by 1,214 · cited 1×
“Given the fact that these mutations occur in exons near intron/exon boundaries, it is highly suggestive that these mutant transcripts are targeted for destruction by the mRNA nonsense-mediated decay pathway (Maquat, 2004).”
BackgroundGATA4 transcription factor is required for ventral morphogenesis and heart tube formation.
Kuo, C. T., Morrisey, E. E., Anandappa, R., Sigrist, K., Lu, M. M., Parmacek, M. S., Soudais, C., & Leiden, J. M. (1997) · Genes & Development · doi:10.1101/gad.11.8.1048 · Cited by 1,037 · cited 4×
“They regulate biological functions, including organogenesis, differentiation, proliferation, and apoptosis (Kuo et al., 1997; Charron et al., 1999; Koutsourakis et al., 1999; Holtzinger and Evans, 2005; Kobayashi et al., 2006; Watt et al., 2007), but their roles in the normal and transformed human central nervous syst…”
InfluentialPollard, S. M., Yoshikawa, K., Clarke, I. D., Danovi, D., Stricker, S., Russell, R., Bayani, J., Head, R., Lee, M., Bernstein, M., et al. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2009.03.014 · Cited by 1,025 · cited 1×
“We screened two GBM BTIC lines generated from operative tissue as previously described (Pollard et al., 2009).”
MethodSelf-citation
Research works printed but not linked: 1
- Kleihues P. Cavanee W.K., editors. 2000. World Health Organization Classification of Tumors: Pathology and Genetic: Tumors of the Nervous System. IARC. 314 pp.
Cited by
The DNA damage response induces inflammation and senescence by inhibiting autophagy of GATA4.
Kang, C., Xu, Q., Martin, T. D., Li, M. Z., Demaria, M., Aron, L., Lu, T., Yankner, B. A., Campisi, J., & Elledge, S. J. (2015) · Science · doi:10.1126/science.aaa5612 · Cited by 982
“Consistent with a regulatory role in senescence, GATA4 is frequently silenced in lung, colon, prostate, ovarian, and breast cancer (38, 39).”
BackgroundEpidemiology of Glioblastoma Multiforme–Literature Review
Grochans, S., Cybulska, A. M., Simińska, D., Korbecki, J., Kojder, K., Chlubek, D., & Baranowska-Bosiacka, I. (2022) · Cancers · doi:10.3390/cancers14102412 · Cited by 630
“[63] showed that: (i) in 94/163 human GBM tumor cells, GATA4 expression was lost, (ii) GATA4 inhibited transformation to GBM in vitro and in vivo, and (iii) the re-expression of GATA4 in GBM cells sensitized them to telosomide, regardless of the MGMT mutation status.”
Agnihotri, S., Burrell, K. E., Wolf, A., Jalali, S., Hawkins, C., Rutka, J. T., & Zadeh, G. (2013) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-012-0203-0 · Cited by 272
Self-citationThe emerging role of GATA transcription factors in development and disease
Lentjes, M. H., Niessen, H. E., Akiyama, Y., de Bruïne, A. P., Melotte, V., & van Engeland, M. (2016) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2016.2 · Cited by 249
“136).”
InfluentialPersonalized treatment strategies in glioblastoma: MGMT promoter methylation status
Thon, N., Kreth, S., & Kreth, F. W. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s50208 · Cited by 166
Agnihotri, S., Gajadhar, A. S., Ternamian, C., Gorlia, T., Diefes, K. L., Mischel, P. S., Kelly, J., McGown, G., Thorncroft, M., Carlson, B. L., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59334 · Cited by 172
Self-citationUnderstanding Glioblastoma Tumor Biology: The Potential to Improve Current Diagnosis and Treatments
Kesari, S. (2011) · Seminars in Oncology · doi:10.1053/j.seminoncol.2011.09.005 · Cited by 155
Self-citationPINK1 Is a Negative Regulator of Growth and the Warburg Effect in Glioblastoma
Agnihotri, S., Golbourn, B., Huang, X., Remke, M., Younger, S., Cairns, R. A., Chalil, A., Smith, C. A., Krumholtz, S.-L., Mackenzie, D., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3079 · Cited by 139
“Stereotactic guided intracranial injections in NOD-SCID mice were performed as previously described(17).”
MethodSelf-citationMolecular mechanisms of temozolomide resistance in glioblastoma multiforme
Johannessen, T.-C. A., & Bjerkvig, R. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.37 · Cited by 142
HPV-related methylation signature predicts survival in oropharyngeal squamous cell carcinomas
Kostareli, E., Holzinger, D., Bogatyrova, O., Hielscher, T., Wichmann, G., Keck, M. K., Lahrmann, B., Grabe, N., Flechtenmacher, C., Schmidt, C. R., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67010 · Cited by 128
UK Testicular Cancer Collaboration, Litchfield, K., The PRACTICAL Consortium, Levy, M., Orlando, G., Loveday, C., Law, P. J., Migliorini, G., Holroyd, A., Broderick, P., et al. (2017) · Nature Genetics · doi:10.1038/ng.3896 · Cited by 127
Comprehensive DNA methylation analysis of benign and malignant adrenocortical tumors
Fonseca, A. L., Kugelberg, J., Starker, L. F., Scholl, U., Choi, M., Hellman, P., Åkerström, G., Westin, G., Lifton, R. P., Björklund, P., et al. (2012) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.21978 · Cited by 88
“…in a number of other cancers including primary melanoma, ovarian cancer, lung cancer, glioblastoma multiforme, and prostate cancer (Guan et al., 2003; Virmani et al., 2003; Akahira et al., 2004; Stone et al., 2004; Terasawa et al., 2004; Das et al., 2006; Martinez et al., 2007; Tam et al., 2007).”
BackgroundmiR-219-5p Inhibits Receptor Tyrosine Kinase Pathway by Targeting EGFR in Glioblastoma
Rao, S. A. M., Arivazhagan, A., Pandey, P., Santosh, V., Hegde, A. S., Chandramouli, B. A., & Somasundaram, K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063164 · Cited by 95
“Cell lines and tumor samples The cell lines U138, U343, U251, U87, 293T and SW480 cells were kind gift from Dr. Abhijit Guha [12] and were grown in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% FBS. U87 parental, U87 - wtEGFR stable cells and U87DEGFR stable cells were kind gift from Dr. Frank Furnari,…”
MethodAgnihotri, S., Burrell, K. E., Buczkowicz, P., Remke, M., Golbourn, B. J., Chornenkyy, Y., Gajadhar, A. S., Fernandez, N. A., Clarke, I. D., Barszczyk, M., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0157 · Cited by 86
Self-citationTumor Metabolism of Malignant Gliomas
Ru, P., Williams, T. M., Chakravarti, A., & Guo, D. (2013) · Cancers · doi:10.3390/cancers5041469 · Cited by 78
“Interestingly, HK2 is expressed in lower levels in the neural subtype, but at higher levels in mesenchymal subtype of GBM [46,47].”
BackgroundMahoney, S. E., Yao, Z., Keyes, C. C., Tapscott, S. J., & Diede, S. J. (2012) · Epigenetics · doi:10.4161/epi.19463 · Cited by 69
Kreth, S., Thon, N., & Kreth, F. W. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.04.008 · Cited by 75
“GATA4, NDRG2 Tumor suppression [21,22]”
BackgroundThe strategy for enhancing temozolomide against malignant glioma
Nakada, M., Furuta, T., Hayashi, Y., Minamoto, T., & Hamada, J. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00098 · Cited by 73
Natrajan, R., Mackay, A. G., Lambros, M. B. K., Weigelt, B., Wilkerson, P. M., Manié, É., Grigoriadis, A. E., A’Hern, R., van der Groep, P., Kozarewa, I., et al. (2012) · The Journal of Pathology · doi:10.1002/path.4003 · Cited by 71
Jy, C., Lo, W.-L., Ko, C.-Y., Chou, S.-Y., Chen, R.-M., Chang, K.-Y., Hung, J.-J., Su, W., Chang, W.-C., & Hsu, T.-I. (2017) · Oncogenesis · doi:10.1038/oncsis.2017.31 · Cited by 62
Testicular Cancer: Genes, Environment, Hormones
Toni, L. D., Šabović, I., Cosci, I., Ghezzi, M., Foresta, C., & Garolla, A. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00408 · Cited by 59
Identification of Functional Mutations in GATA4 in Patients with Congenital Heart Disease
Wang, E., Sun, S., Qiao, B., Duan, W., Huang, G., An, Y., Xu, S., Zheng, Y., Su, Z., Gu, X., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062138 · Cited by 61
Chemoresistance and Chemotherapy Targeting Stem-Like Cells in Malignant Glioma
Sørensen, M. D., Fosmark, D. S., Hellwege, S., Beier, D., Kristensen, B. W., & Beier, C. P. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-16537-0_7 · Cited by 58
GATA4 loss of function in liver cancer impedes precursor to hepatocyte transition
Enane, F. O., Shuen, T. W. H., Gu, X., Ebrahem, Q., Przychodzen, B. P., Makishima, H., Bodo, J., Ng, J., Chee, C. L., Ba, R., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci93488 · Cited by 54
Using a preclinical mouse model of high-grade astrocytoma to optimize p53 restoration therapy
Shchors, K., Persson, A. I., Rostker, F., Tihan, T., Lyubynska, N., Li, N., Swigart, L. B., Berger, M. S., Hanahan, D., Weiss, W. A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219142110 · Cited by 48
Functional and Sustainable 3D Human Neural Network Models from Pluripotent Stem Cells
Cantley, W. L., Du, C., Lomoio, S., DePalma, T. J., Peirent, E. R., Kleinknecht, D., Hunter, M., Tang‐Schomer, M. D., Tesco, G., & Kaplan, D. L. (2018) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.8b00622 · Cited by 48
“GATA4, while commonly used as a genetic marker for endoderm has also been shown to be present in human neurons and a negative regulator of astrocytes (30, 31), which could explain the increased expression levels observed.”
Backgroundp62 acts as an oncogene and is targeted by miR-124-3p in glioma
Deng, D., Luo, K., Liu, H., Nie, X., Xue, L., Wang, R., Xu, Y., Cui, J., Shao, N., & Zhi, F. (2019) · Cancer Cell International · doi:10.1186/s12935-019-1004-x · Cited by 47
Negroni, C., Hilton, D. A., Ercolano, E., Adams, C., Kurian, K. M., Baiz, D., & Hanemann, C. O. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102941 · Cited by 47
Prediction of cancer driver genes through network-based moment propagation of mutation scores
Gumpinger, A., Lage, K., Horn, H., & Borgwardt, K. M. (2020) · Bioinformatics · doi:10.1093/bioinformatics/btaa452 · Cited by 38
Targeting DNA repair and the cell cycle in glioblastoma
Alexander, B. M., Pinnell, N. E., Wen, P. Y., & D’Andrea, A. D. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0765-4 · Cited by 40
“Furthermore, preclinical research has shown that inhibition of BER in glioma cell lines overexpressing N-methylpurine DNA glycosylase (MPG), a DNA glycosylase involved in BER, potentiates the effects of TMZ [49].”
Jorde, A., Bach, P., Witt, S. H., Becker, K., Reinhard, I., Vollstädt‐Klein, S., Kirsch, M., Hermann, D., Charlet, K., Beck, A., et al. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.10.020 · Cited by 39
Xu, H., Cao, J., Xu, J., Li, H., Shen, H., Li, X., Wang, Z., Wu, J., & Chen, G. (2019) · Experimental Neurology · doi:10.1016/j.expneurol.2019.01.018 · Cited by 32
“GATA-4 was also shown to mediate astrocyte proliferation by regulating p21 (Cip1), which caused glioblastoma multiforme (Agnihotri et al., 2011).”
InfluentialThe multi-omic landscape of transcription factor inactivation in cancer
Teschendorff, A. E., Zheng, S., Feber, A., Yang, Z., Beck, S., & Widschwendter, M. (2016) · Genome Medicine · doi:10.1186/s13073-016-0342-8 · Cited by 32
“Similarly, GATA factors such as GATA4 play key roles in the development of the gastrointestinal tract [37–39] as well as in the development of the heart [40], pancreas [41] and liver [42], and so these factors could play tumour-suppressor roles in many different cancer types [39, 43].”
BackgroundGenome-wide analysis of circular RNAs involved in Marek’s disease tumourigenesis in chickens
Wang, L., You, Z., Wang, M., Yuan, Y., Liu, C., Yang, N., Zhang, H., & Lian, L. (2020) · RNA Biology · doi:10.1080/15476286.2020.1713538 · Cited by 40
“In this study, miR-155 in ceRNA network acted as hub gene, and five DE mRNA targets were identified, such as GATA4, which participated in the regulation of disease occurrence [44,45].”
BackgroundAn Update on the Epigenetics of Glioblastomas
Ferreira, W. A. S., Pinheiro, D. D. R., da Costa, C. A., Rodrigues-Antunes, S., Araújo, M. D., Barros, M. B. L., Teixeira, A. C. D. S., Faro, T. A. S., Burbano, R. M. R., de Oliveira, E. H. C., et al. (2016) · Epigenomics · doi:10.2217/epi-2016-0040 · Cited by 30
Zhu, X., Yuan, R., Hood, L., & Ao, P. (2015) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2015.01.004 · Cited by 26
Koncar, R. F., Dey, B., Stanton, A.-C. J., Agrawal, N., Wassell, M., McCarl, L. H., Locke, A. L., Sanders, L., Vaske, O. M., Myers, M. I., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3521 · Cited by 26
Self-citationA Novel Missense Mutation of GATA4 in a Chinese Family with Congenital Heart Disease
Zhang, X., Wang, J., Wang, B., Chen, S., Fu, Q., & Sun, K. (2016) · PLoS ONE · doi:10.1371/journal.pone.0158904 · Cited by 24
“By cooperating with target genes, GATA4 can regulate multiple processes essential for normal cardiac morphogenesis [10].”
BackgroundGATA4 promotes hepatoblastoma cell proliferation by altering expression of miR125b and DKK3
Pei, Y., Yao, Q., Yuan, S., Xie, B., Liu, Y., Ye, C., & Zhuo, H. (2016) · Oncotarget · doi:10.18632/oncotarget.12839 · Cited by 23
“Loss of GATA4 expression occurs in many cancers, including epithelial ovarian cancer, adrenocortical tumors, hepatocellular carcinoma, and colorectal cancer, indicating that GATA4 may be a tumor suppressor [16].”
BackgroundHan, X., Tang, J., Chen, T., & Ren, G. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27455 · Cited by 22
“initiation and development of human cancer.(7,8) Although the antitumorigenic function of GATA4 has been demonstrated to be associated with direct activation of the cell cycle inhibitor p21 independent of TP53 in malignant human astrocytomas,(8) it is unclear whether and how it acts as a tumor suppressor in human BrCa.”
BackgroundXiang, Q., Zhou, D., He, X., Fan, J., Tang, J., Qiu, Z., Zhang, Y., Qiu, J., Xu, Y., & Lai, G. (2019) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.14684 · Cited by 21
Yin, A., Shang, Z., Etcheverry, A., He, Y., Aubry, M., Lü, N., Liu, Y., Mosser, J., Lin, W. J., Zhang, X., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1902071 · Cited by 20
“Gene related to other identified CpGs have also been reported to have implications in immunity and cancer including gliomas such as COX4I2,(44) ELMO3,(45) TRIM40,(46,47) and GATA4.(48,49) Future studies will be needed to explore the biological relevance of the specific molecular mechanism of S100A2 on FGL2 expression…”
BackgroundZhou, Q., Mahati, S., Kugeluke, Y., Fu, Q., Li, S., & Dilimulati, Y. (2022) · BMC Neuroscience · doi:10.1186/s12868-022-00736-6 · Cited by 19
“Based on previous literature, NHAs could be driven towards a tumorenhancing phenotype via some molecular networks [51].”
MethodTao, Y., Fang, F., Hu, S., Lu, J., Cao, L., Zhao, W., Xiao, P.-F., Li, Z., Wang, N., Xu, L., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1760-5 · Cited by 20
“GATA4 reduced expression of APNG (alkylpurine-DNA-N-glycosylase), a DNA repair enzyme which is poorly characterized in GBM-mediated temozolomide resistance [23].”
BackgroundGATA4 immunolocalization in breast carcinoma as a potent prognostic predictor
Takagi, K., Moriguchi, T., Miki, Y., Nakamura, Y., Watanabe, M., Ishida, T., Yamamoto, M. P., Sasano, H., & Suzuki, T. (2014) · Cancer Science · doi:10.1111/cas.12382 · Cited by 20
GATA4 and DcR1 methylation in glioblastomas
Vaitkienė, P., Skiriutė, D., Skauminas, K., & Tamašauskas, A. (2013) · Diagnostic Pathology · doi:10.1186/1746-1596-8-7 · Cited by 20
“6% (94/163) GBM operative samples and it was a negative survival prognostic marker [6].”
BackgroundResultInfluentialDickkopf-3 in Human Malignant Tumours: A Clinical Viewpoint
Lee, E., Nguyen, Q. T. T., & Lee, M.-Y. (2020) · Anticancer Research · doi:10.21873/anticanres.14617 · Cited by 17
Cho, D. I., Kang, W. S., Hong, M. H., Kang, H. J., Kim, M. R., Kim, M. C., Kim, Y. S., & Ahn, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.17471 · Cited by 17
“GATA4 is a negative regulator of normal astrocyte proliferation and suppresses tumor cell growth through direct activation of p21 [35].”
BackgroundProgress on siRNA-based gene therapy targeting secondary injury after intracerebral hemorrhage
Almarghalani, D. A., & Shah, Z. A. (2021) · Gene Therapy · doi:10.1038/s41434-021-00304-3 · Cited by 17
Bose, D., Vaigundan, D., Shetty, M., Krishnappa, J., & Kutty, A. V. M. (2017) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2017.08.001 · Cited by 15
“GATA4 (Gene Id: 2626, OMIM: 600576) is a critical transcription factor expressed in embryo and adult cardiomyocytes and it promotes cardiac morphogenesis, survival and function of the heart [11].”
BackgroundLiu, X., Liu, L., Wu, A., Huang, S., Xu, Z., Zhang, X., Li, Z., Li, H., & Dong, J. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14599 · Cited by 16
“40 Overexpression of APNG was disclosed in several malignancies, including gliomas, breast, and ovarian cancer, which decreased the sensitivity of cancer cells to alkylating agents, especially for TMZ.”
BackgroundBelaguli, N. S., Zhang, M., Garcia, A.-H., & Berger, D. H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035717 · Cited by 13
TP53-PTEN-NF1 depletion in human brain organoids produces a glioma phenotype in vitro
Singh, S. K., Wang, Y., Habib, A., Mamindla, P., Kodavali, C. V., Chen, A., Ma, W., Wang, J., Hameed, N. U. F., Hu, B., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1279806 · Cited by 13
Self-citationGuo, C., Xu, Y., Han, X., Liu, X., Xie, R., Cheng, Z., & Fu, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.736225 · Cited by 13
“injected homologous glioma cells with high expression of GATA4 into nude mice and found that the control group with high expression of GATA4 survived with tumor-free, whereas the treatment group died of malignant glioma within 31 ± 7 days after injection (47).”
MethodLi, B., Liu, Y., Zhang, P., Song, X., Wang, X., Zheng, Z., & Pei, D. (2025) · Plant Biotechnology Journal · doi:10.1111/pbi.70207 · Cited by 11
“In mammals, numerous studies have implicated GATA4 in playing a crucial role in diverse cancer-related biological processes, encompassing apoptosis, proliferation and metastasis (Agnihotri et al ., 2011; Kang et al ., 2015).”
Astrocytes in glioblastoma tumor microenvironment
Cui, S., Guan, F., Li, X., Long, X., & Wu, M. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189518 · Cited by 12
Han, Q., Xu, X. P., Li, J., Jinggang, W., Bai, L., Wang, A., Wang, W., & Zhang, B. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.7369 · Cited by 12
“Previous studies have reported that the expression of GATA4 was low in several cancers, including colorectal cancer, adrenocortical tumors, epithelial ovarian cancer and hepatocellular carcinoma, which suggested that GATA4 may serve as a tumor suppressor (35).”
Shafi, O., Siddiqui, G., & Jaffry, H. A. (2023) · BMC Cancer · doi:10.1186/s12885-023-11723-3 · Cited by 10
“GATA4 plays a very significant role in differentiation process also by governing genes associated with cell-to-cell adhesion, cytoskeleton organization and extracellular matrix dynamics; this promotes them to become more differentiated and less proliferative [78].”
BackgroundNanoparticle encapsulation enables systemic IGF-Trap delivery to inhibit intracerebral glioma growth
Chen, Y. M., Chambon, J., Moquin, A., Hashimoto, M., Perrino, S., Leibovitch, M., Benslimane, Y., Haçarız, O., Yang, Q., Nakano, I., et al. (2025) · Neuro-Oncology · doi:10.1093/neuonc/noaf011 · Cited by 9
da Fonseca, C. O., Soares, I. D. P., Clemençon, D. S., Rochlin, S., Cardeman, L., & Quírico‐Santos, T. (2015) · Journal of Histology and Histopathology · doi:10.7243/2055-091x-2-12 · Cited by 8
“Indeed, elevated levels of alkyl purine DNA glycosylase (APNG) other DNA base excision repair enzyme that directly repairs alkylated bases at N7 guanine and N3 adenine is associated with poor overall survival [33].”
BackgroundPossible mechanism of GATA4 inhibiting myocardin activity during cardiac hypertrophy
Xu, Y., Liang, C., Luo, Y., Xing, W., & Zhang, T. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28178 · Cited by 8
“GATA4 is a zinc finger‐containing transcription factor that plays a central role in tissue‐specific gene expression in various tissues such as the heart.(9-12) In particular, GATA4 binding is required for the transcriptional activity of downstream target gene promoters.”
BackgroundLam, L. K. M., Tien, T., Wildung, M. R., White, L. A., Sellon, R. K., Fidel, J. L., & Shelden, E. A. (2022) · PLoS ONE · doi:10.1371/journal.pone.0273705 · Cited by 8
A GATA4-regulated tumor suppressor network represses formation of malignant human astrocytomas
Agnihotri, S., Wolf, A., Muñoz, D. M., Smith, C., Gajadhar, A. S., Restrepo, A., Clarke, I. D., Fuller, G. N., Kesari, S., Dirks, P. B., et al. (2011) · The Journal of Cell Biology · doi:10.1083/jcb1932oia3 · Cited by 7
Self-citationSOX9 Protein in Pancreatic Cancer Regulates Multiple Cellular Networks in a Cell-Specific Manner
Kopantzev, E. P., Kondratyeva, L. G., Kopantseva, M. R., Кашкин, К. Н., Gnatenko, D. A., Grigorieva, E., Алексеенко, И. В., Safina, D. R., & Чернов, И. П. (2022) · Biomedicines · doi:10.3390/biomedicines10071466 · Cited by 6
“In glioblastoma cells, an increase in GATA4 levels can lead to TP53-independent upregulation of CDKN1A and cell growth suppression [44].”
BackgroundGATA Transcription Factors: A Cross‐Road for Erythropoiesis, Neurodevelopment, and Synucleinopathies
Bellomi, F. E., Caturano, C., Velardi, V., Mancinelli, R., Carotti, S., Vivacqua, G., Arciprete, F., & Zingariello, M. (2025) · Developmental Neurobiology · doi:10.1002/dneu.22975 · Cited by 6
“In the brain, GATA4 plays a key role in regulating normal cell growth, specifically by preventing astrocytes from becoming cancerous through the control of cell proliferation and apoptosis (Agnihotri et al. 2011).”
Nawaito, S. A., Esmael, M., Souchkova, O., Cardinal, T., Bernas, G., Bergeron, K., Gayda, F., Bergeron, F., Bouchard, M., Zhou, X., et al. (2025) · The FASEB Journal · doi:10.1096/fj.202401718rr · Cited by 5
Brain tumor-initiating cells and cells of origin in glioblastoma
Agnihotri, S., Muñoz, D. M., Zadeh, G. M., & Guha, A. (2011) · Translational Neuroscience · doi:10.2478/s13380-011-0037-y · Cited by 5
“Also, these BTIC cells expressing stably expressing GATA4 were more sensitive to temozolomide, a chemotherapeutic that has clinical efficacy in treatment of GBM patients [58,59].”
BackgroundSelf-citationBrain Tumor Metabolism — Unraveling Its Role in Finding New Therapeutic Targets
Miranda‐Gonçalves, V., Baltazar, F., & Reis, R. M. (2015) · InTech eBooks · doi:10.5772/59606 · Cited by 5
“As the first enzyme involved in the glycolytic pathway, HK controls glucose flux in glycolysis or the pentose phosphate pathway (PPP) [38].”
BackgroundUbiquitin Proteasome Gene Signatures in Ependymoma Molecular Subtypes
Vriend, J. P., Thanasupawat, T., Sinha, N., & Klonisch, T. C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012330 · Cited by 5
“GATA4 has been found to be a tumor suppressor in astrocytomas [132].”
BackgroundLi, Y., Wei, Y., Yuan, W., Huang, Q., Zhao, Y., Zhao, W., Xu, W. D., & Wu, J. (2018) · Oncology Reports · doi:10.3892/or.2018.6310 · Cited by 5
“Cycle conditions were as previously described (13).”
BackgroundLeader, A. M., Neil, A., Siegmund, S., Dehghani, A., Ligon, A. H., Matulonis, U. A., Nucci, M. R., McCluggage, W. G., Howitt, B. E., & Kolin, D. L. (2025) · Modern Pathology · doi:10.1016/j.modpat.2025.100891 · Cited by 2
Using mice to unveil the genetics of cancer resistance
van der Weyden, L., & Adams, D. J. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.05.003 · Cited by 3
[Establishment and verification of a mouse model of Gata4 gene H435Y mutation].
Zhang, H., Chen, M., Fang, T., Zhang, T., & Ni, W. (2018) · Europe PMC (PubMed Central) · doi:10.3969/j.issn.1673-4254.2018.10.15 · Cited by 2
“[24]Agnihotri S, Wolf A, Munoz DM, et al.”
BackgroundPotential Prognostic Value of GATA4 Depends on the p53 Expression in Primary Glioblastoma Patients
Trąbska-Kluch, B., Braun, M., Orzechowska, M., Paszek, S., Zuchowska, A., Sołek, J. M., Kluska, A., Fijuth, J., Jesionek‐Kupnicka, D., & Zawlik, I. (2023) · Genes · doi:10.3390/genes14061146 · Cited by 1
“GATA4 silencing can be achieved through promoter hypermethylation or novel somatic mutations associated with the inter alia loss of heterozygosity (LOH) [4].”
BackgroundInfluentialLentjes, M. H. F. M. (2016) · Research Publications (Maastricht University) · doi:10.26481/dis.20161202ml · Cited by 1
Manoranjan, B., Vora, P., Venugopal, C., & Singh, S. K. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-396967-5.00019-0 · Cited by 1
Vaitkienė, P. (2013) · Laba (Lietuvos akademinių bibliotekų direktorių asociacija)
Areeb, Z. (2020) · Minerva Access (University of Melbourne) · Cited by 1
Glioblastoma Multiforme Metabolism: Fuel to the Flame
Sridharan, P. (2016) · Annals of SBV · doi:10.5005/jp-journals-10085-5112
GATA4 Is a Transcriptional Regulator of SOX2 in Japanese Flounder (Paralichthys olivaceus)
Liu, X., Li, Z., Yan, W., Zhao, H., Liu, Y., Han, M., Wang, X., He, Y., Yu, H., & Zhang, Q. (2022) · Journal of Ocean University of China · doi:10.1007/s11802-022-4806-8
“In addition, one line of evidence indicates that human GATA4 regulates apoptosis-related genes in cultured glioblastoma multiforme cell lines (Agnihotri et al., 2011).”
BackgroundChernov, A. N., Galimova, E. S., & Валерьевна, Ш. О. (2022) · Medical academic journal · doi:10.17816/maj83594
Agnihotri, S., Burrell, K. E., Buczkowicz, P., Remke, M., Golbourn, B. J., Chornenkyy, Y., Gajadhar, A. S., Fernandez, N. A., Clarke, I. D., Barszczyk, M. S., et al. (2023) · doi:10.1158/2159-8290.22530770
Self-citationZhou, Q., Mahati, S., Kugeluke, Y., Fu, Q., Li, S., & Dilimulati, Y. (2022) · Figshare · doi:10.6084/m9.figshare.21152066
Zhou, Q., Mahati, S., Kugeluke, Y., Fu, Q., Li, S., & Dilimulati, Y. (2022) · Figshare · doi:10.6084/m9.figshare.21152069
Zhou, Q., Mahati, S., Kugeluke, Y., Fu, Q., Li, S., & Dilimulati, Y. (2022) · Figshare · doi:10.6084/m9.figshare.21152072
Zhou, Q., Mahati, S., Kugeluke, Y., Fu, Q., Li, S., & Dilimulati, Y. (2022) · Figshare · doi:10.6084/m9.figshare.21152063
Zhou, Q., Mahati, S., Kugeluke, Y., Fu, Q., Li, S., & Dilimulati, Y. (2022) · Figshare · doi:10.6084/m9.figshare.21152060
Epigenetic Mechanisms of Glioblastoma
Brimo, N., Denkbaş, E. B., & Çakar, B. (2025) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815324181125010005
Molecular Genetics of Glioblastoma (GBM)
Brimo, N., Denkbaş, E. B., & Cakar, B. (2025) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815324181125010004
Glioblastoma: Overview of the pathogenesis, clinical features, and diagnosis
Karwal, A., Kumar, A., Yadav, A. K., & Kumar, A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33319-4.00002-1
Zhou, Q., Mahati, S., Kugeluke, Y., Fu, Q., Li, S., & Dilimulati, Y. (2022) · Figshare · doi:10.6084/m9.figshare.21152054
Zhou, Q., Mahati, S., Kugeluke, Y., Fu, Q., Li, S., & Dilimulati, Y. (2022) · Figshare · doi:10.6084/m9.figshare.21152057
The role of GATA transcription factors in treatment-induced senescence in non-small cell lung cancer
Hietarinne, J. (2023) · UTUPub (University of Turku)
Revisiting GATA4 – Multifunctional transcriptional factor of oncogenesis
Dharshini, L. C. P., Rasmi, R. R., Sakthivel, K. M., & Muniandi, B. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119477
DNA hydroxymethylation-mediated epigenetic modifications in alcohol use disorder
Kannan, S. R., Santhoshkumar, K., & Tamizhselvi, R. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1858336
A Gata4–Loxl2 axis controls ECM remodeling to enable scar-free spinal cord regeneration in zebrafish
Noel, N. P., Fernandes, V. F. L., Kjar, A., Pfotenhauer, P. E., Kim, H., Sefogbe, M. P., Akam, E. A., Lippmann, E. S., & Cigliola, V. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.118050
Metadata
- Authors
- Agnihotri, S., Wolf, A., Munoz, D. M., Smith, C. J., Gajadhar, A., Restrepo, A., Clarke, I. D., Fuller, G. N., Kesari, S., Dirks, P. B., McGlade, C. J., Stanford, W. L., Aldape, K., Mischel, P. S., Hawkins, C., & Guha, A.
- Affiliations
- University of Toronto (CA)
- The Arthur and Sonia Labatt’s Brain Tumor Research Centre, The Hospital for Sick Children’s Research Institute 1 , 2 , 3 , and 4
- The University of Texas MD Anderson Cancer Center (US)
- University of California San Diego (US)
- University of California, Los Angeles (US)
- Corresponding author
- Guha, Abhijit
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2011-04-04
- Volume
- 208
- Issue
- 4
- Pages
- 689-702
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC3135351
- OpenAlex
- W2167377849
- Cited by
- 92
- References
- 53
- Citations by year
- 2026: 3 · 2025: 9 · 2024: 1 · 2023: 4 · 2022: 10 · 2021: 3 · 2020: 5 · 2019: 5 · 2018: 5 · 2017: 6 · 2016: 8 · 2015: 6 · 2014: 2 · 2013: 10 · 2012: 9
- FWCI
- 4.38
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- cc-by-nc-sa
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › FOXO transcription factor regulation
- Keywords
- GATA4, glioblastoma, astrocytoma, tumor suppressor, transcription factors, promoter hypermethylation, Ras activation, p53 deficiency, p21 Cip1, temozolomide sensitivity, MGMT, DNA repair, cancer stem cells, neurospheres, cell cycle inhibition, prognostic factors
- MeSH terms
- Temozolomide, Animals, Brain Neoplasms, Dacarbazine, Glioblastoma, Humans, Promoter Regions, Genetic, DNA Modification Methylases, DNA Methylation, Cyclin D1, Tumor Suppressor Proteins, DNA Repair Enzymes, Cell Line, Tumor, Cell Proliferation, Cyclin-Dependent Kinase Inhibitor p21, GATA4 Transcription Factor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.